Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,146
- Phase 21,063
- Phase 1820
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis140
- Type 1 Diabetes134
- Atopic Dermatitis130
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections113
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland195
- Alabama176
- Florida145
- Arizona141
- New York122
- Massachusetts119
- Texas118
- Illinois81
- Colorado76
Recruiting studies6,230 total
- NCT07408024RecruitingPhase 2
TollB-001 tablets for moderate to severe rheumatoid arthritis
This trial tests an experimental tablet, TollB-001, for people with moderate to severe rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and effective.
Bengbu, AnhuiAges 18–70 - NCT07408219Recruiting
Study of Remibrutinib for chronic hives
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
East Hanover, New JerseyAges 18–100 - NCT07408336RecruitingEarly Phase 1
Study of AFN50 injection for active lupus
This study tests an investigational injection called AFN50 for people whose lupus (SLE) remains active despite standard treatments. The goal is to see if the drug can safely help control lupus symptoms better than current therapies alone.
Hefei, AnhuiAges 18–69 - NCT07409701Recruiting
Gamification help for kids with type 1 diabetes
This study tests if a game-based app helps children aged 8 to 12 manage their type 1 diabetes better. It could make learning about diabetes more fun and engaging.
Ankara, YenimahalleAges 8–12 - NCT07410039RecruitingPhase 4
Acute treatment for neuromyelitis optica in real-world setting
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
BeijingAges 18–65 - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT07410624Recruiting
Kidney function in brain injury patients
This trial measures how quickly the kidneys clear drugs in patients with serious brain conditions like stroke or meningitis. It may help doctors adjust medicine doses for better treatment.
Lexington, KentuckyAges 18–85 - NCT07410637Recruiting
Thyroid hormones and energy in graves' or thyroid cancer
This trial studies how thyroid hormone levels affect your body's use of sugar and energy. It may help people newly diagnosed with Graves' disease or thyroid cancer understand their metabolism better.
Ulm, Baden-WurttembergAges Any age - NCT07411755RecruitingPhase 1
Comparing a new biologic (GS101) with Dupixent in healthy volunteers
This trial tests a new biologic medicine (GS101) against an approved treatment (Dupixent) for conditions like atopic dermatitis. It is looking for healthy volunteers to compare how the body processes each drug after an injection under the skin.
Suzhou, JiangsuAges 18–55 - NCT07412990Recruiting
Grass pollen allergy treatment in real life
This study looks at how well the grass pollen allergy treatment Grassmuno® works in everyday life. It is for adults with moderate to severe hay fever triggered by grass pollen, who may or may not have well-controlled asthma.
HamburgAges 18 years+ - NCT07413341RecruitingPhase 1
Study of new drug TI-0032-III for hard-to-treat autoimmune diseases
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07413809RecruitingPhase 3
Preventing nausea after stem cell transplant: olanzapine vs dexamethasone
This trial compares two anti-nausea drug regimens (one with olanzapine, one with dexamethasone) to prevent delayed nausea and vomiting after a stem cell transplant for multiple myeloma. It aims to find which is better at controlling these side effects.
Ningbo, ZhejiangAges 18–65 - NCT07413835Recruiting
Study of HN2302 for hard-to-treat myasthenia gravis
This trial tests a new medicine called HN2302 for people with generalized myasthenia gravis (MG) that hasn't improved with standard treatments. It aims to see if HN2302 is safe and helps reduce muscle weakness symptoms.
Xuzhou, JiangsuAges 18–80 - NCT07414758RecruitingPhase 3
Golidocitinib vs placebo for PTCL maintenance after first chemo
This trial tests whether a daily pill called golidocitinib can keep your PTCL from coming back after you've had a good response to your first chemotherapy. The study compares the drug to a placebo (a pill with no active medicine) to see if it helps prevent relapse.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07415551RecruitingPhase 2
New drug for chronic hives that don't respond to allergy pills
This study tests an investigational medication called lesigercept for people with chronic hives that don't get better with standard allergy pills. The goal is to see if it can reduce itching and hives better than placebo.
Sofia, SofiaAges 18–75 - NCT07415824Recruiting
Multiple Sclerosis Registry Study
This study creates a registry for people with multiple sclerosis (MS) to track their health over time. The information gathered may help researchers better understand MS and improve care.
Cherry Hill, New JerseyAges 18 years+ - NCT07416162Recruiting
Study of iptacopan for PNH or C3G in Korea
This trial tests a medicine called iptacopan for people with paroxysmal nocturnal hemoglobinuria (a rare blood disorder) or C3 glomerulopathy (a kidney disease). It aims to see if the drug is safe and effective for Korean patients.
JeollanamAges 18–99 - NCT07416201Recruiting
Study of Immune System Aging in Down Syndrome
This study is looking at how the immune system changes over time in people with Down syndrome, and how it may be affected by removal of the thymus gland. The goal is to understand why people with Down syndrome may age faster or have different immune health.
Bethesda, MarylandAges 1–120 - NCT07416656Recruiting
Checking blood sugar test accuracy for arthritis patients on sulfasalazine
This study checks if the medicine sulfasalazine affects a blood sugar test (HbA1c) in people with inflammatory arthritis. If you have arthritis, take sulfasalazine, and have higher blood sugar or diabetes, this trial may help understand your glucose levels.
Silkeborg, Central JutlandAges 18 years+ - NCT07418190RecruitingPhase 2
Combination therapy for relapsed follicular lymphoma
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
Nanjing, JiangsuAges 18–75 - NCT07418385Recruiting
Voluntary HIV testing for adults in France
This study offers free, voluntary HIV testing to anyone in France who is 18 or older. It aims to make HIV screening easy and accessible, regardless of your sexual history or past testing.
ReimsAges 18 years+ - NCT07419243RecruitingPhase 1/Phase 2
Tolerance in milk and egg allergy in children
This study watches how milk and egg allergies change naturally over time or after oral immunotherapy (OIT) in children. It helps researchers understand how the immune system adapts, aiming to improve treatment for food allergies.
Madrid, MadridAges 4–17 - NCT07419230Recruiting
Digital tool to help with allergy shot adherence
This trial tests a digital tool designed to help patients stick to their allergy immunotherapy schedule. If you have allergic rhinitis (with or without asthma) and are starting a new single-allergy treatment, you may be able to join.
Madrid, MadridAges Any age - NCT07420296RecruitingPhase 3
Modified zipper therapy for AQP4-positive neuromyelitis optica
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
TianjinAges 18–80
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,786 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.